
|Articles|February 1, 2022
Daily Medication Pearl: Bupropion (Aplenzin)
Author(s)Saro Arakelians, PharmD
Bupropion (Aplenzin) is an antidepressant that treats major depressive disorder and seasonal affective disorder.
Advertisement
Medication Pearl of the Day: Bupropion (Aplenzin)
Indication: Bupropion (Aplenzin) is an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD) and seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient.
Insight:
- Dosing: Starting dose 174 mg once daily (equivalent to 150 mg bupropion HCl). Usual target dose 348 mg once daily (equivalent to 300 mg bupropion HCl).
- Dosage forms: Extended-release tablets 174 mg, 348 mg, and 522 mg.
- Adverse events: Most common adverse reactions are (incidence ≥5%; ≥2× placebo rate) dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, and rash.
- Mechanism of action: The mechanism of action of bupropion is unknown, as is the case with other antidepressants; however, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms.
- Manufacturer: Valeant Pharma
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The ABCs of Vitamin D Supplements: Exploring Their Health Benefits and Proper Use
2
Occupational Factors Can Increase Risk of Long COVID
3
Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy
4
Aficamten Receives FDA Approval for Obstructive Hypertrophic Cardiomyopathy
5





































































































































































































